People: Arena Pharmaceuticals Inc (ARNA.OQ)
19 Jul 2019
Dr. Preston S. Klassen M.D. M.H.S. is an Executive Vice President - Research & Development, Chief Medical Officer of the Company. Dr. Klassen has served as our Executive Vice President, Research and Development and Chief Medical Officer since March 2017. Most recently, he was Chief Medical Officer of Laboratoris Sanifit S.L. from May 2016 to March 2017, and was Executive Vice President, Head of Global Development at Orexigen Therapeutics, Inc. from November 2009 to May 2016. Previously, Dr. Klassen held several positions of increasing responsibility at Amgen Inc., including Therapeutic Area Head for Nephrology. Prior to joining Amgen, he was a faculty member in the Division of Nephrology at Duke University Medical Center. In March 2018, Orexigen filed a voluntary Chapter 11 petition in the United States Bankruptcy Court for the District of Delaware. Dr. Klassen serves on the board of Conatus Pharmaceuticals Inc., a biotechnology company focused on developing and commercializing novel medicines to treat liver disease. Dr. Klassen received his medical degree from the University of Nebraska College of Medicine and completed his residency in internal medicine, fellowship in nephrology, and masters in health sciences degree at Duke University.
|Total Annual Compensation, USD||667,369|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||2,412,480|
|Fiscal Year Total, USD||3,079,840|